ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Therapeutic Inhibition of Spleen Tyrosine Kinase Decreases Hepatic Damage after Ischemia Reperfusion Injury

A. Zarrinpar, V. Boominathan, A. Kobayashi, S. Duarte

Surgery, University of Florida, Gainesville, FL

Meeting: 2020 American Transplant Congress

Abstract number: C-361

Keywords: Ischemia

Session Information

Session Name: Poster Session C: Ischemia Reperfusion & Organ Rehabilitation

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Hepatic ischemia/reperfusion injury (IRI) is a major challenge in transplantation. The complex array of interrelated signaling events in IRI have been studied individually, but effective clinical treatments have yet to be developed. We recently performed a comparative multi-omic analysis in both a mouse model of hepatic IRI and post-reperfusion biopsies from human orthotopic liver transplants. Our analysis corroborated previously implicated signals. However, we also identified the tyrosine kinase Syk as a potential target for decreasing IRI. Syk is an important mediator of neutrophil activation in inflammation, but it has not been studied in the context of IRI. Therefore, in this study we build on our previous findings and examine the impact of this kinase on neutrophil activation in liver IRI.

*Methods: 10-12 week old mice were subjected to 70% partial warm ischemia for 60 minutes, followed by 6 and 24 hours of reperfusion. The treatment (Syk inhibitor R788) group was treated for 5 days prior to IRI. Untreated mice were used as controls. Sham operations were used as negative controls. Blood and hepatic tissue were collected at each time point for analysis. Standard flow cytometry of whole blood was performed for the cell specific markers Ly-6G, CD11b, CD4, F4/80, CD38 and CD45RA to identify specific neutrophil subpopulations.

*Results: Combined flow cytometry and immunohistochemical analysis revealed that specific Syk inhibition with R788 significantly reduced neutrophil activation and recruitment to the liver after reperfusion, when compared to the control group (Figure). In association with the reduced recruitment of activated neutrophils, the Syk inhibitor pre-treated group showed significantly lower levels of plasma ALT, confirming an improved and protective effect on the liver function after IRI at 6h and persisted up to 24h compared to the control group.

*Conclusions: This study confirms previous findings from the multi-omic analysis, demonstrates the power of this approach in finding potential drug targets and specifically reveals that the tyrosine kinase Syk is an important mediator of neutrophil activation and recruitment in hepatic IRI. Moreover, it provides supportive evidence for the potential future use of specific Syk inhibitors in clinical treatment of hepatic IRI after liver transplantation.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Zarrinpar A, Boominathan V, Kobayashi A, Duarte S. Therapeutic Inhibition of Spleen Tyrosine Kinase Decreases Hepatic Damage after Ischemia Reperfusion Injury [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/therapeutic-inhibition-of-spleen-tyrosine-kinase-decreases-hepatic-damage-after-ischemia-reperfusion-injury/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences